A woman happily resting head on a mans shoulder

Help us detect cancer early
with a blood draw.

Join a clinical study to develop blood tests that detect multiple types of cancers.

Early detection matters

5-year survival rate 8X higher

Cancer is found too late. For example, only 15% of lung cancers are diagnosed in stage I/II.1

Cancer screening can save lives and improve cancer survival rates by finding the disease at an earlier stage when it is more likely to be curable, especially for cancers like colorectal and lung. For lung cancer, the 5-year survival rate is 8x higher when found early compared to after it spreads.2

The Sanderson Study

The Sanderson Study is part of our multi-cancer research program focused on developing next-generation blood tests to detect cancer in its earliest, most treatable stages.

The study aims to develop blood tests that can provide accurate, convenient and patient-friendly options for cancer screening.

A woman happily resting head on a mans shoulder

Freenome clinical studies are named in honor of Freenome employees’ loved ones who battled cancer.

The Sanderson Study is named in honor of Tim Sanderson, the loving father of a Freenome engineer.

Who can participate

The study is enrolling individuals age 30 and over who are willing to provide a blood sample:

Cancer participants

Our study is looking for people who have been diagnosed with cancer and have not yet received treatment.

Non-cancer participants

We are also looking for participants who do not have signs or symptoms of cancer, or a known cancer diagnosis.*

For more information: www.clinicaltrials.gov

*Additional eligibility criteria apply. Please speak with your healthcare provider for more details.

Older woman with glasses smiling Older woman with glasses smiling

Three steps to participate

Those who participate in the non-cancer group will receive a follow up via phone or medical records review one year after blood draw.

Three steps to participate

  1. Talk to your healthcare provider to find out if you qualify to enroll in The Sanderson Study
  2. Get a standard blood draw. No medications or treatments are part of this study
  3. Receive your stipend and our thanks
Email for more information

Frequently asked questions

What is the purpose of The Sanderson Study?

The Sanderson Study is part of Freenome’s multi-cancer research program. The Sanderson Study is Freenome’s first study for the detection of multiple cancers that pairs multiomics with real-world data and is designed to bridge clinical research with day-to-day clinical impact.

What do you mean by multi-cancer?

We are developing blood tests that detect multiple types of cancer. Since different cancers have different underlying biology, Freenome believes in a tailored approach for multi-cancer screening. This ensures each test is optimized for each cancer’s unique screening needs.

What multi-cancer research studies do you have right now?

Currently we are enrolling for two multi-cancer studies. The Vallania Study is our research study and the Sanderson Study is intended for clinical validation. With all of our research programs, our goal is to better understand patterns for certain types of cancers so we can develop cancer screening tests that are accurate, convenient, and patient-friendly.

What other clinical studies has Freenome conducted?

Freenome has a history of large, diverse clinical trials. Freenome conducted the PREEMPT CRC study, the largest clinical study validating a blood-based colorectal cancer screening test. PREEMPT CRC completed study enrollment in May 2022 with over 35,000 participants with diversity across racial, ethnic and socioeconomic backgrounds.

Why is the study named The Sanderson Study?

Freenome clinical studies are named in honor of Freenome employees’ loved ones who battled cancer. The Sanderson Study is named in honor of Tim Sanderson, the loving father of a Freenome engineer.

What is the time commitment required to participate in the study?

Participation in The Sanderson Study requires a standard blood draw and answering a few questions about your medical background.

If I participate, will I receive my test results?

Any diagnostic tests and results that may be part of your individual medical care will continue to come directly from your doctor. As the Freenome product is under development, you will not receive a Freenome test report as part of this study.

Will I be compensated?

Yes, you will be compensated if you enroll and complete the requirements of the study.

Which cancer types are being studied in The Sanderson Study?

The Sanderson Study is looking at multiple cancer types. Cancer types studied may differ by study location, please contact us for details.

Scientist holding a rack of test tubes

About Freenome

Freenome, a biotechnology company, has pioneered a comprehensive platform for early cancer detection using a standard blood draw. The company combines its expertise in molecular biology with advanced computational biology and machine learning to recognize disease-associated patterns among billions of biomarkers.

References
  1. “Promoting Early Detection and Treatment of Cancer”. Centers for Disease Control and Prevention. Accessed November 21, 2021. https://www.cdc.gov/cancer/ncccp/priorities/early-detection-treatment.htm
  2. Participants in the non-cancer group will be followed up after one year on cancer status. This can be either a medical records review or telephone contact.

279 East Grand Avenue
5th Floor
South San Francisco CA
94080

Notice of privacy practices

Privacy policy

© 2023 Freenome Holdings, Inc.

FREENOME is a registered trademark of Freenome Holdings, Inc. All rights reserved.